Financial giants have made a conspicuous bearish move on Madrigal Pharmaceuticals. Our analysis of options history for Madrigal Pharmaceuticals MDGL revealed 10 unusual trades.
Delving into the details, we found 30% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $615,511, and 2 were calls, valued at $185,300.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $260.0 to $350.0 for Madrigal Pharmaceuticals over the recent three months.
Volume & Open Interest Trends
In today's trading context, the average open interest for options of Madrigal Pharmaceuticals stands at 112.75, with a total volume reaching 372.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Madrigal Pharmaceuticals, situated within the strike price corridor from $260.0 to $350.0, throughout the last 30 days.
Madrigal Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MDGL | PUT | SWEEP | BULLISH | 01/16/26 | $72.0 | $66.6 | $70.95 | $290.00 | $213.1K | 0 | 4 |
| MDGL | CALL | TRADE | BEARISH | 07/19/24 | $6.6 | $2.9 | $3.5 | $350.00 | $160.3K | 144 | 0 |
| MDGL | PUT | SWEEP | BULLISH | 01/16/26 | $74.1 | $71.5 | $71.81 | $290.00 | $143.4K | 0 | 68 |
| MDGL | PUT | SWEEP | NEUTRAL | 01/16/26 | $74.8 | $66.5 | $71.18 | $290.00 | $56.8K | 0 | 34 |
| MDGL | PUT | SWEEP | BULLISH | 01/16/26 | $74.5 | $66.5 | $70.94 | $290.00 | $56.7K | 0 | 52 |
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
In light of the recent options history for Madrigal Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Madrigal Pharmaceuticals's Current Market Status
- Currently trading with a volume of 379,455, the MDGL's price is down by -2.77%, now at $283.9.
- RSI readings suggest the stock is currently may be overbought.
- Anticipated earnings release is in 55 days.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Madrigal Pharmaceuticals with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
